Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Der Urologe. Ausg. A - 1 Sept 2008

Hadaschik B A, Zhang K, So A I, Bell J C, Thüroff J W, Rennie P S, Gleave M E

Abstract excerpt

Patients with high-risk bladder cancer who do not respond to bacillus Calmette-Guerin (BCG) immunotherapy represent a significant therapeutic challenge. The addition of interferon to BCG has recently evolved as a second-line treatment option; however, many high-grade tumors are nonresponsive to i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Interferons
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Transplantation

Share to Oncolytic Virotherapy

Share to Tumor Burden

Share to Urinary Bladder

Share to Vesicular stomatitis Indiana virus

Source

Identifiers

PMID: 18670747
DOI: 10.1007/s00120-008-1827-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18670747-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].PMID 18670747Read ↗

Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid StructuresSemantic proximity Read ↗

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerSemantic proximity Read ↗

Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistanceSemantic proximity Read ↗

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Semantic proximity Read ↗

Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer modelsSemantic proximity Read ↗

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.Semantic proximity Read ↗

Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder CancerSemantic proximity Read ↗

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Semantic proximity Read ↗

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver CancersSemantic proximity Read ↗

Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?Semantic proximity Read ↗

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.Semantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic VectorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.